Evidence map›Paper›PMID 29982877›Full record

ArticlePediatric nephrology (Berlin, Germany)2018

Use of genomic and functional analysis to characterize patients with steroid-resistant nephrotic syndrome.

Thomas M Kitzler, Nadezda Kachurina, Martin M Bitzan, Elena Torban, Paul R Goodyer

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Thomas M KitzlerDepartment of Medical Genetics, The Montreal Children's Hospital, McGill University Health Center, Montreal, Quebec, Canada.
Nadezda KachurinaDepartment of Medicine, McGill University and McGill University Health Center, Montreal, Quebec, Canada.
Martin M BitzanDivision of Nephrology, The Montreal Children's Hospital, McGill University Health Center, 1001 Boulevard Décarie, Room EM1.2232, Montreal, Quebec, H4A 3J1, Canada.
Elena TorbanDepartment of Medicine, McGill University and McGill University Health Center, Montreal, Quebec, Canada.
Paul R GoodyerDivision of Nephrology, The Montreal Children's Hospital, McGill University Health Center, 1001 Boulevard Décarie, Room EM1.2232, Montreal, Quebec, H4A 3J1, Canada. paul.goodyer@mcgill.ca.
Montreal Children's Hospital · CAMcGill University Health Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChildren with genetic causes of steroid-resistant nephrotic syndrome (SRNS) usually do well after renal transplantation, while some with idiopathic SRNS show recurrence due to a putative podocyte-toxic factor. Distinguishing different forms of SRNS based on clinical criteria has been difficult. The aim of our study was to test a novel approach that allows categorization of patients into clinically useful subgroups.

methodsSeventeen patients with clinically confirmed SRNS were analyzed by next-generation sequencing (NGS) of 37 known SRNS genes and a functional assay of cultured human podocytes, which indirectly tests for toxicity of patients' sera by evidenced loss of podocyte focal adhesion complex (FAC) number.

resultsWe identified a pathogenic mutation in seven patients (41%). Sera from patients with monogenic SRNS caused mild loss of FAC number down to 73% compared to untreated controls, while sera from seven of the remaining ten patients with idiopathic SRNS caused significant FAC number loss to 43% (non-overlapping difference 30%, 95% CI 26-36%, P < 0.001). All patients with recurrent SRNS (n = 4) in the graft showed absence of podocyte gene mutations but significant FAC loss. Three patients had no mutation nor serum podocyte toxicity.

conclusionsOur approach allowed categorization of patients into three subgroups: (1) patients with monogenic SRNS; (2) patients with idiopathic SRNS and marked serum podocyte toxicity; and (3) patients without identifiable genetic cause nor evidence of serum podocyte toxicity. Post-transplant SRNS recurrence risk appears to be low in groups 1 and 3, but high in group 2.

Indexed as

AdolescentAdultCell Culture TechniquesCell LineChildChild, PreschoolDrug ResistanceFemaleGlucocorticoidsHigh-Throughput Nucleotide SequencingHumansMaleMutationNephrotic SyndromePodocytesRecurrenceGlucocorticoidsFocal segmental glomerulosclerosisFunctional podocyte assayNext-generation sequencingRecurrent FSGSSteroid-resistant nephrotic syndrome

Identifiers

PMID29982877
OpenAlexW2857550791

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.